Biodexa Pharmaceuticals Files 6-K Report
Ticker: BDRX · Form: 6-K · Filed: Jan 22, 2025 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Jan 22, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
Biodexa Pharma (fka Midatech) filed a 6-K, standard foreign issuer report.
AI Summary
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on January 22, 2025. The filing is a report of a foreign private issuer and indicates the company will file annual reports under Form 20-F. The company is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Biodexa Pharmaceuticals PLC's status as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- Biodexa Pharmaceuticals PLC (company) — Filer
- Midatech Pharma Plc (company) — Former company name
- January 22, 2025 (date) — Filing date
- 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (location) — Company address
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is January 22, 2025.
What is the principal executive office address of Biodexa Pharmaceuticals PLC?
The principal executive office address is 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Has Biodexa Pharmaceuticals PLC changed its name previously?
Yes, the company was formerly known as Midatech Pharma Plc, with a date of name change on June 2, 2015.
Does Biodexa Pharmaceuticals PLC file annual reports under Form 20-F or 40-F?
Biodexa Pharmaceuticals PLC indicates it files annual reports under cover of Form 20-F.
Filing Stats: 245 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2025-01-22 08:30:27
Filing Documents
- f6k_012225.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-25-000361.txt ( ) — 15KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC (Registrant) Date: January 22, 2025 /s/ Stephen Stamp Stephen Stamp Chief Executive Officer, Chief Financial Officer